Table of Contents Author Guidelines Submit a Manuscript
Depression Research and Treatment
Volume 2012, Article ID 393251, 4 pages
http://dx.doi.org/10.1155/2012/393251
Research Article

A Pilot Study of Mifepristone in Combat-Related PTSD

1Department of Psychiatry, James J. Peters VA Medical Center, Bronx, NY 10468, USA
2Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029-6574, USA

Received 21 November 2011; Revised 23 December 2011; Accepted 13 February 2012

Academic Editor: Alexander McFarlane

Copyright © 2012 Julia A. Golier et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. N. Sarkar, “Mifepristone: bioavailability, pharmacokinetics and use-effectiveness,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 101, no. 2, pp. 113–120, 2002. View at Publisher · View at Google Scholar
  2. A. M. Karssen, J. K. Belanoff, and E. R. de Kloet, “Glucocorticoid receptor antagonist C-1073 (mifepristone/RU486) inhibits P-glycoprotein-mediated efflux transport of cortisol,” in Proceedings of the 34th Congress of International Society of Psychoneuroendocrinology, New York, NY, USA, 2003.
  3. J. K. Belanoff, A. J. Rothschild, F. Cassidy et al., “An open label trial of C-1073 (mifepristone) for psychotic major depression,” Biological Psychiatry, vol. 52, no. 5, pp. 386–392, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Buckley, V. Duggal, and A. F. Schatzberg, “The acute and post-discontinuation effects of a glucocorticoid receptor (GR) antagonist probe on sleep and the HPA axis in chronic insomnia: a pilot study,” Journal of Clinical Sleep Medicine, vol. 4, no. 3, pp. 235–241, 2008. View at Google Scholar · View at Scopus
  5. R. Yehuda, J. A. Golier, R. K. Yang, and L. Tischler, “Enhanced sensitivity to glucocorticoids in peripheral mononuclear leukocytes in posttraumatic stress disorder,” Biological Psychiatry, vol. 55, no. 11, pp. 1110–1116, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. J. D. Bremner, J. Licinio, A. Darnell et al., “Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder,” American Journal of Psychiatry, vol. 154, no. 5, pp. 624–629, 1997. View at Google Scholar · View at Scopus
  7. D. G. Baker, S. A. West, W. E. Nicholson et al., “Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder,” American Journal of Psychiatry, vol. 156, no. 4, pp. 585–588, 1999. View at Google Scholar · View at Scopus
  8. A. H. Young, P. Gallagher, S. Watson, D. Del-Estal, B. M. Owen, and I. N. Ferrier, “Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder,” Neuropsychopharmacology, vol. 29, no. 8, pp. 1538–1545, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Gallagher, S. Watson, M. S. Smith, I. N. Ferrier, and A. H. Young, “Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia,” Biological Psychiatry, vol. 57, no. 2, pp. 155–161, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. C. DeBattista, J. Belanoff, S. Glass et al., “Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression,” Biological Psychiatry, vol. 60, no. 12, pp. 1343–1349, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Nikzad, A. A. Vafaei, A. Rashidy-Pour, and S. Haghighi, “Systemic and intrahippocampal administrations of the glucocorticoid receptor antagonist RU38486 impairs fear memory reconsolidation in rats,” Stress, vol. 14, no. 4, pp. 459–464, 2011. View at Publisher · View at Google Scholar
  12. B. Rearte, A. Maglioco, L. Balboa et al., “Mifepristone (RU486) restores humoral and T cell-mediated immune response in endotoxin immunosuppressed mice,” Clinical and experimental immunology, vol. 162, no. 3, pp. 568–577, 2010. View at Google Scholar